PTC Therapeutics, Inc.
PTCT
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.8B
$69.30
▼ -2.94%
P/E
-140.28
Mkt Cap
$5.8B
52-Wk Range
$56.51–$90.87
52-Week Range
$56.51 - $90.87
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 21.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary RNA splicing platform technology enabling targeted genetic medicine development
- Established regulatory expertise in rare disease approvals across multiple jurisdictions
- Commercial infrastructure and partnerships enabling global market access in underserved regions
- First-mover advantage in key rare disease indications with limited competitive alternatives
- Strategic collaborations with pharmaceutical giants (Roche) and disease foundations accelerating R&D
Bear Case
2 risks
- Low volatility (beta 0.5).
- High premium - requires strong execution
Growth
Turning profitable
Strong revenue growth (115% YoY)
Value
High premium - requires strong execution
Momentum
Stable
-2.2% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PTCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
JUL 30, 2026
Reported EPS of $0.92 vs $0.24 consensus (+289.3% surprise). Revenue of $360.5M vs $298.6M expected (+20.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+289.3%
Revenue trend · last 8Q
—
-31%
+460%
-4%
+7%
-23%
-77%
+102%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$196.8M
$213.2M
$1.2B
$178.9M
$211.0M
$164.7M
$272.6M
$360.5M
Margins · last 8Q
Gross
0.0%
Operating
41.3%
Profit
23.2%
Wall Street consensus
8 analysts · 88% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
88%
Hold
13%
Sell
0%
Median Price Target
—
Latest: Barclays · Aug 14, 2026
vs Industry
How PTCT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related